Ingo J. Diel

from Wikipedia, the free encyclopedia
Ingo J. Diel, 2017

Ingo Jakob Diel (born October 26, 1950 in Bingen am Rhein ) is a German doctor , gynecologist , gyneco-oncologist, osteo-oncologist and cancer researcher. Diel is considered to be an important representative of modern osteo-oncology, which researches the mutual relationship between tumor, tumor therapy and the skeleton. He became known for the significant discovery that the early use of osteoprotectants can lower the frequency of later bone metastases in breast cancer patients. His scientific work on bone protection preparations such as bisphosphonates and RANK-Ligant antibodies ( denosumab ) represent further research focuses .

Career

Ingo J. Diel is the son of the farmer Ingo Diel and his wife Alice (née Charlier) and grandson of the politician Jakob Diel and spent childhood and youth on the Schlossgut Diel winery in Burg-Layen on the lower Nahe. He attended the humanistic branch of the Stefan-George-Gymnasium in Bingen am Rhein .

After graduating from high school, Diel first worked in nursing in clinics in Frankfurt am Main and Heidelberg. He then studied philosophy and, since 1976, human medicine at the Ruprecht-Karls-Universität Heidelberg . He received his doctorate in 1982 under the chair of pathology Wilhelm Doerr . His doctoral thesis at the pathological institute dealt with the establishment of an animal model for the generation of bone metastases (doctoral supervisor: Burkhart Krempien). This topic has shaped his scientific career. After 2 years as an assistant doctor at the Institute for Pathology , Diel moved to the University Women's Clinic in Heidelberg (Director Gunther Bastert ). His scientific interest was the detection, prognosis and therapy of bone metastases in women with breast cancer . He established a test procedure for the detection of tumor cells in the bone marrow of women with breast cancer as a prognostic factor for a later skeletal metastasis (today: Liquid Biopsy ). On this subject, he completed his habilitation at the University Women's Clinic in Heidelberg in 1993. Since then, Diel has been involved in clinical research into bone protection products such as bisphosphonates and denosumab (osteoprotectants). In August 1998 he published the world's first paper on the prevention of bone metastases by bisphosphonates in breast cancer patients with tumor cells in the bone marrow (The New England Journal of Medicine: Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment ). In 1999, he was recognized as a specialist in gynecology and obstetrics by the Baden-Württemberg State Medical Association and was appointed an Apl. Professor . He ended his clinic career in 2001 as managing senior physician at the Heidelberg University Women's Clinic in order to set up a practice clinic with a focus on gynecology in Mannheim . His clinical and scientific interest there lies in the care of women with metastatic disease and patients with tumor therapy-induced osteoporosis .

In addition to his clinical and surgical activities, Diel is known for around 200 scientific publications and book chapters. Diel gives numerous lectures at national and international congresses. He is known for his contributions to the advanced and advanced training of doctors and patients, as well as for his active support of self-help groups such as Mamazone and Breast Cancer Germany. For the breast cancer magazine Mama Mia! Since 2006, Diel has been writing a column every three months on the topic of breast cancer - "Myths and facts", which is primarily aimed at affected women.

specialization

Diel is an expert in breast cancer and gynecological tumors . He specializes in the treatment of women with metastatic disease with a focus on bone metastases . Another focus is the treatment of patients with primary and tumor therapy-induced osteoporosis .

Awards

For his "pioneering achievements in the prevention of bone metastases through the bisphosphonate drug group", Diel received the German patient award "Busenfreund 2003" from Mamazone - Women and Research Against Breast Cancer eV in 2003. Since 2002 he has been counted among the top doctors in Germany in the FOCUS list.

Memberships

Diel is a member of numerous national and international scientific associations.

Scientific publications

A total of around 200 articles by Diel can be found in international and German specialist magazines. Much of his professional articles appeared in English.

In addition to the following selection of fonts, there are other publications from Diel's profile page on research gate.

  • About the generation of artificial bone metastases with the hypercalcemic Walker Carcinosarcom 256 in rats, inaugural dissertation, Ruprecht-Karls-Universität Heidelberg 1982, German National Library
  • Prognostic significance of tumor cell detection in the bone marrow of patients with primary breast cancer , habilitation thesis, Ruprecht-Karls-Universität Heidelberg 1993
  • Detection of Tumor Cells in Bone Marrow of Patients With Primary Breast Cancer: A Prognostic Factor for Distant Metastasis. J Clin Oncol 1992; 10: 1534-1539
  • Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-166
  • Current use of bisphosphonates in oncology. J Clin Oncol 1998: 16: 3890-3899
  • Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63
  • Osteoporosis due to cancer treatment. J Clin Oncol 2000; 18: 1570-1593
  • Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur. J. Cancer 2004; 40: 1704-1712
  • A pooled analysis of bone marrow micrometastases in breast cancer. New Engl J Med 2005; 353: 793-802
  • Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer. 2007; 15: 1243-9
  • Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 2007; 196: 342.e1-9.
  • Adjuvant oral clodronate improves overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008; 19: 2007-11
  • Incidence, risk factors, and outcome of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-7
  • German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013; 31: 3531-9
  • The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer 2015; 51: 1467-75
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyzes of individual patient data from randomized trials. Lancet. 2015 Oct 3; 386 (10001): 1353-61. Epub 2015 Jul 23.2015
  • Safety of long term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 Jan; 24 (1): 447-55. Epub 2015 Sep 3.

Books

  • Metastatic Bone Disease. Fundamental and Clinical Aspects, Springer, Berlin, Heidelberg, New York, 1994.
  • Bisphosphonates in oncology, Unimed-Verlag, Bremen, 1999.
  • Therapy options for bone metastases. S. Karger Publishing House. Basel, Freiburg 2007

Web links

Individual evidence

  1. ↑ Ingo J. Diel, Erich-Franz Solomayer, Serban D. Costa, Christina Gollan, Ronald Goerner: Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment . In: New England Journal of Medicine . tape 339 , no. 6 , August 6, 1998, ISSN  0028-4793 , p. 357-363 , doi : 10.1056 / NEJM199808063390601 ( online [accessed May 5, 2020]).
  2. ↑ Ingo J. Diel: About the generation of artificial bone metastases with the hypercalciemic Walker carcinosarcom 256 in the rat . ( dnb.de [accessed on May 5, 2020]).
  3. ↑ Ingo J. Diel: Prognostic significance of tumor cell detection in the bone marrow of patients with primary breast cancer . ( dnb.de [accessed on May 5, 2020]).
  4. ↑ Ingo J. Diel, Erich-Franz Solomayer, Serban D. Costa, Christina Gollan, Ronald Goerner: Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment . In: New England Journal of Medicine . tape 339 , no. 6 , August 6, 1998, ISSN  0028-4793 , p. 357-363 , doi : 10.1056 / NEJM199808063390601 ( online [accessed May 4, 2020]).
  5. ↑ Laudation Busenfreund 2003 (PDF) mamazone.de. Retrieved May 27, 2020.
  6. ↑ Prof. Dr. med. Ingo J. Diel . focus-arztsuche.de. Retrieved May 27, 2020.
  7. ↑ Ingo Diel . researchgate.net. Retrieved May 27, 2020.
  8. ↑ Ingo J. Diel: About the generation of artificial bone metastases with the hypercalciemic Walker carcinosarcom 256 in the rat . ( dnb.de [accessed on May 11, 2020]).
  9. ↑ Ingo J. Diel: Prognostic significance of tumor cell detection in the bone marrow of patients with primary breast cancer . ( dnb.de [accessed on May 5, 2020]).
  10. ^ IJ Diel, M Kaufmann, R Goerner, SD Costa, S Kaul: Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. In: Journal of Clinical Oncology . tape 10 , no. October 10 , 1992, ISSN  0732-183X , p. 1534–1539 , doi : 10.1200 / JCO.1992.10.10.1534 ( online [accessed May 4, 2020]).
  11. ^ IJ Diel, M. Kaufmann, SD Costa, R. Holle, G. von Minckwitz: Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal Status . In: JNCI Journal of the National Cancer Institute . tape 88 , no. 22 , November 20, 1996, ISSN  0027-8874 , pp. 1652–1658 , doi : 10.1093 / jnci / 88.22.1652 ( online [accessed May 4, 2020]).
  12. ↑ JJ Body, R Bartl, P Burckhardt, PD Delmas, IJ Diel: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. In: Journal of Clinical Oncology . tape 16 , no. December 12 , 1998, ISSN  0732-183X , p. 3890–3899 , doi : 10.1200 / JCO.1998.16.12.3890 ( online [accessed May 4, 2020]).
  13. ↑ Ingo J. Diel, Erich-Franz Solomayer, Serban D. Costa, Christina Gollan, Ronald Goerner: Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment . In: New England Journal of Medicine . tape 339 , no. 6 , August 6, 1998, ISSN  0028-4793 , p. 357-363 , doi : 10.1056 / NEJM199808063390601 ( online [accessed May 4, 2020]).
  14. ↑ Johannes Pfeilschifter, Ingo J. Diel: Osteoporosis Due to Cancer Treatment: Pathogenesis and Management . In: Journal of Clinical Oncology . tape 18 , no. 7 , April 7, 2000, ISSN  0732-183X , p. 1570–1593 , doi : 10.1200 / JCO.2000.18.7.1570 ( online [accessed May 4, 2020]).
  15. ^ IJ Diel, J.-J Body, MR Lichinitser, ED Kreuser, W Dornoff: Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer . In: European Journal of Cancer . tape 40 , no. 11 , July 2004, p. 1704–1712 , doi : 10.1016 / j.ejca.2004.03.025 ( online [accessed May 4, 2020]).
  16. ↑ Stephan Braun, Florian D. Vogl, Bjørn Naume, Wolfgang Janni, Michael P. Osborne: A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer . In: New England Journal of Medicine . tape 353 , no. 8 , August 25, 2005, ISSN  0028-4793 , p. 793-802 , doi : 10.1056 / NEJMoa050434 ( online [accessed May 4, 2020]).
  17. ↑ Ingo J. Diel: Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review . In: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer . tape 15 , no. November 11 , 2007, ISSN  0941-4355 , p. 1243 , doi : 10.1007 / s00520-007-0244-9 , PMID 17393190 .
  18. ↑ Florian Schuetz, Ingo J. Diel, Marit Pueschel, Thomas von Holst, Erich F. Solomayer: Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy . In: American Journal of Obstetrics and Gynecology . tape 196 , no. 4 , April 2007, pp. 342.e1–342.e9 , doi : 10.1016 / j.ajog.2006.10.901 ( online [accessed on May 11, 2020]).
  19. ^ IJ Diel, A. Jaschke, EF Solomayer, C. Gollan, G. Bastert: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow — a long-term follow-up . In: Annals of Oncology . tape 19 , no. December 12 , 2008, pp. 2007–2011 , doi : 10.1093 / annonc / mdn429 , PMID 18664560 , PMC 2733118 (free full text) - ( Online [accessed May 4, 2020]).
  20. ↑ F. Saad, JE Brown, C. Van Poznak, T. Ibrahim, SM Stemmer: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases . In: Annals of Oncology . tape 23 , no. 5 , May 2012, p. 1341–1347 , doi : 10.1093 / annonc / mdr435 ( online [accessed May 4, 2020]).
  21. ↑ Gunter von Minckwitz, Volker Möbus, Andreas Schneeweiss, Jens Huober, Christoph Thomssen: German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer . In: Journal of Clinical Oncology . tape 31 , no. 28 , October 1, 2013, ISSN  0732-183X , p. 3531–3539 , doi : 10.1200 / JCO.2012.47.2167 ( online [accessed May 4, 2020]).
  22. ↑ Ingo J. Diel, Jean-Jacques Body, Alison T. Stopeck, Saroj Vadhan-Raj, Andrew Spencer: The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease . In: European Journal of Cancer . tape 51 , no. 11 , July 2015, p. 1467–1475 , doi : 10.1016 / j.ejca.2015.04.017 ( online [accessed May 4, 2020]).
  23. ↑ Adjuvant bisphosphonate treatment in early breast cancer: meta-analyzes of individual patient data from randomized trials . In: The Lancet . tape 386 , no. 10001 , October 2015, p. 1353-1361 , doi : 10.1016 / S0140-6736 (15) 60908-4 ( online [accessed May 4, 2020]).
  24. ↑ Alison T. Stopeck, Karim Fizazi, Jean-Jacques Body, Janet E. Brown, Michael Carducci: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer . In: Supportive Care in Cancer . tape 24 , no. 1 , January 2016, ISSN  0941-4355 , p. 447–455 , doi : 10.1007 / s00520-015-2904-5 , PMID 26335402 , PMC 4669370 (free full text) - ( Online [accessed May 4, 2020]).
  25. ^ Metastatic Bone Disease . 1994, doi : 10.1007 / 978-3-642-78596-2 ( online [accessed May 12, 2020]).
  26. ^ Ingo J Diel, Kurt Possinger: Bisphosphonate in der Onkologie . UNI-MED Verl., Bremen 1999, ISBN 978-3-89599-426-5 ( worldcat.org [accessed on May 12, 2020]).
  27. ↑ Ingo J Diel, Reiner Bartl: Therapy options for bone metastases from metastatic breast cancer . Karger, Basel; Freiburg (Breisgau); Paris; London; New York; New Delhi; Bangkok; Singapore; Tokyo; Sydney 2007, ISBN 978-3-8055-8223-0 ( Online [accessed May 12, 2020]).
personal data
SURNAME Diel, Ingo J.
ALTERNATIVE NAMES Diel, Ingo Jakob
BRIEF DESCRIPTION German doctor, gynecologist, gyneco-oncologist, osteo-oncologist and cancer researcher
DATE OF BIRTH October 26, 1950
PLACE OF BIRTH Bingen am Rhein